{"id":"W4387811267","doi":"10.1016/j.annonc.2023.09.2157","title":"1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Stephenson Cancer Center; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; Genentech; Foundation Medicine; Sierra Oncology; INCLIVA Instituto de Investigación Sanitaria; Sun Pharma; PharmaMar; University of Toronto; European Society for Medical Oncology; FibroGen; Cytokinetics; Astellas Pharma; Eisai; Pfizer; Moderna; Incyte; BeiGene; Natera; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; Gilead Sciences; Ribon Therapeutics; Array BioPharma; Iterion Therapeutics; Sanofi; Amgen; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Rash; Mucositis; Gastroenterology; Internal medicine; Colorectal cancer; Phases of clinical research; Diarrhea; Toxicity; Adverse effect; Cancer; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000379406,0.0001379264,0.0005820573,0.0001790917,0.00003294355,0.000001281851,0.0001756428,0.0002222462,0.0002753864],"category_scores_gemma":[0.00006255875,0.0000967992,0.00005899203,0.0004907831,0.0002527712,0.00003871096,0.00005790843,0.0001924426,0.000007494557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001735599,"about_ca_system_score_gemma":0.0000948536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000227281,"about_ca_topic_score_gemma":0.000356348,"domain_scores_codex":[0.9986252,0.0003669797,0.0003902646,0.000249661,0.00005004617,0.0003178284],"domain_scores_gemma":[0.9991489,0.0002528196,0.0002104335,0.0001590576,0.0002066113,0.00002219382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01446362,0.01244048,0.36941,0.00002637423,0.0008683093,0.00001997511,0.002083926,0.00003500021,0.08688751,0.00007032925,0.002957694,0.5107368],"study_design_scores_gemma":[0.02718424,0.05938144,0.7769833,0.00003797865,0.00005212384,0.000001321017,0.001165004,0.000006844502,0.11895,0.0001064246,0.01588748,0.0002439124],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977435,0.0005140987,0.000001508265,0.0005094378,0.0002516695,0.0004977349,0.00007088065,0.00001830102,0.0003928799],"genre_scores_gemma":[0.9990828,0.0004073648,0.00005822652,0.0002480819,0.000009202362,0.00005104102,0.00002034095,0.00001098789,0.0001119691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5104929,"threshold_uncertainty_score":0.3947357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07137095289724445,"score_gpt":0.4252981760145111,"score_spread":0.3539272231172667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}